How I Manage HCC Risk Following HCV Cure
Hepatitis C Update: A Growing Challenge With Evolving Management Solutions
GS-108: Switch From TDF to TAF Associated With Improvements in Bone and Renal Markers in HBeAg-Negative Patients
MAGELLAN-3 Interim Analysis: High SVR12 Rate Achieved With GLE/PIB Plus SOF and RBV in HCV-Infected Patients With HCV Infection With Previous GLE/PIB Failure
Second Interim Analysis of STREAGER: High Rate of SVR With 8 Weeks of Elbasvir/Grazoprevir in Treatment-Naive Patients With Nonsevere Fibrosis and Genotype 1b HCV Infection
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Clinical Care Options, LLC. All Rights Reserved.